FDA Fees to Review Drugs Would Be Unfrozen in House Bill

FDA Fees to Review Drugs Would Be Unfrozen in House Bill

The FDA is supposed to collect $720 million for brand-name drugs, $299 million for generic medicines and $98 million from device companies this fiscal year, according to a Congressional Budget Office assessment. Some of the money currently being paid

5
Like
Save

Comments

Write a comment

*